MedTrace Logo

ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study

NCT00525577 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1012

Last updated 2008-02-06

No results posted yet for this study

Summary

This double-blind, placebo-controlled, dose-finding study is designed to identify the lowest AGI-1067 dose that improves glycemic control as measured by HbA1c and fasting glucose in subjects with Type 2 diabetes mellitus. Glycemic control will be measured during a 6-month treatment period in subjects who are on 1 or no antidiabetic drugs

Conditions

Interventions

DRUG

Placebo

Placebo tablet, once daily

DRUG

AGI-1067

75 mg AGI-1067 tablet, once daily

DRUG

AGI-1067

150 mg AGI-1067 Tablet, once daily

Sponsors & Collaborators

  • AtheroGenics

    lead INDUSTRY

Principal Investigators

  • Walker Long, MD · AtheroGenics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-06-30
Completion
2008-09-30

Countries

  • United States
  • Bosnia and Herzegovina
  • Georgia
  • India
  • North Macedonia
  • Serbia and Montenegro
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525577 on ClinicalTrials.gov